Αρχική World News Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous...

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

Updated results from the phase III KEYNOTE-407 study reported at the European Lung Cancer Virtual Congress 2021 (25-27 March) demonstrated that survival and response rates remained improved with pembrolizumab plus chemotherapy over placebo plus chemotherapy in treatment-naive patients with metastatic squamous non-small cell lung cancer (NSCLC).

Andrew G. Robinson of the Cancer Centre of Southeastern Ontario at Kingston General Hospital in Kingston, Canada presented long-term findings from the KEYNOTE-407 study (NCT02775435) including in patients who received up to 35 cycles or approximately 2 years of pembrolizumab.

A prior report from the protocol-specified final analysis in May 2019 showed that patients with previously untreated metastatic squamous NSCLC receiving pembrolizumab plus carboplatin together with paclitaxel or nab-paclitaxel had significantly improved overall survival (OS) compared to those receiving only chemotherapy (hazard ratio [HR] 0.71; 95% confidence interval [CI] 0.58–0.88).

The randomised, double-blind, phase III KEYNOTE-407 study compared pembrolizumab at 200 mg plus chemotherapy in 278 patients versus placebo plus chemotherapy in 281 patients every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles. Chemotherapy consisted of carboplatin plus a taxane (paclitaxel or nab-paclitaxel). The patients were stratified according to paclitaxel versus nab-paclitaxel, East Asia versus rest of the world, and PD-L1 tumour proportion score (TPS) ≥1% versus <1%.

The primary endpoints of this study were OS and progression-free survival (PFS) per RECIST v1.1 by blinded independent central review.

Patients completing 35 pembrolizumab cycles showed the most improved outcomes

On 30 September 2020, the median time from randomisation to data cutoff was 40.1 (range, 33.1 to 49.4) months. By this time, 143 (51.1%) patients had crossed over from the placebo/chemotherapy arm to receive either pembrolizumab monotherapy on study or received another anti−PD-(L)1 therapy.

OS was improved with the addition of pembrolizumab to chemotherapy; median OS with pembrolizumab/chemotherapy was 17.2 compared to 11.6 months with placebo/chemotherapy (HR 0.71; 95% CI 0.59−0.86). Three-year OS rates of 29.7% versus 18.2% were observed with pembrolizumab/chemotherapy versus placebo/chemotherapy, respectively.

Longer-Follow-Up-Continues-to-Support-First-Line-Pembrolizumab-Plus-Chemotherapy-in-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer

Pembrolizumab plus chemotherapy continued to provide a benefit in overall survival over placebo plus chemotherapy with over 3 years of follow-up.

© Andrew G. Robinson.

The median PFS was also improved with the addition of pembrolizumab to chemotherapy, 8.0 versus 5.1 months (HR 0.59; 95% CI 0.49−0.71); the 3-year PFS rates were 16.1% with pembrolizumab versus 6.5% with placebo. In the respective treatment groups, median PFS2 was 13.8 versus 9.1 months (HR 0.59; 95% CI 0.49−0.71).

Adding pembrolizumab to chemotherapy improved the objective response rate (ORR) to 62.6% compared to 38.8% with placebo/chemotherapy and the median duration of response was 9.0 (range, 1.3+ to 45.0+) months compared to 4.9 (range, 1.3+ to 44.8+) months, respectively.

Among the 55 patients completing 35 cycles of pembrolizumab, the ORR was 92.7%, which included 5 patients with complete response and 46 with partial response; 4 (7.3%) patients had stable disease. After completion of 35 pembrolizumab cycles, 51 (92.7%) patients were alive. The 1-year OS and PFS rates from completion of pembrolizumab were 96.0% and 82.6%, respectively. As of data cut-off, 7 patients had initiated a second course of pembrolizumab.

The incidence of Grade 3−5 adverse events was similar in both arms, at 74.8% with pembrolizumab/chemotherapy and 70.0% with placebo/chemotherapy.

Conclusions

Based upon these findings, the authors concluded that pembrolizumab plus chemotherapy continued to demonstrate durable benefit with >3 years of follow-up as compared to placebo plus chemotherapy, without additional toxicity.

They noted that the majority of patients completing 35 cycles showed objective responses and were alive at data cut-off.

According to the authors, these long-term data continue to support pembrolizumab plus chemotherapy as first-line treatment in patients with metastatic squamous NSCLC.

This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Reference

97O – Robinson AG, Vicente D, Tafreshi A, et al. First-Line Pembrolizumab Plus Chemotherapy for Patients With Advanced Squamous NSCLC: 3-Year Follow-up From KEYNOTE-407. European Lung Cancer Virtual Congress 2021 (25-27 March).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...